JP2022517324A5 - - Google Patents

Info

Publication number
JP2022517324A5
JP2022517324A5 JP2021539056A JP2021539056A JP2022517324A5 JP 2022517324 A5 JP2022517324 A5 JP 2022517324A5 JP 2021539056 A JP2021539056 A JP 2021539056A JP 2021539056 A JP2021539056 A JP 2021539056A JP 2022517324 A5 JP2022517324 A5 JP 2022517324A5
Authority
JP
Japan
Prior art keywords
nrp
seq
antibody
inhibitor
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021539056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517324A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/050039 external-priority patent/WO2020141199A1/en
Publication of JP2022517324A publication Critical patent/JP2022517324A/ja
Publication of JP2022517324A5 publication Critical patent/JP2022517324A5/ja
Priority to JP2024151582A priority Critical patent/JP2024170509A/ja
Pending legal-status Critical Current

Links

JP2021539056A 2019-01-03 2020-01-02 癌を患っている被験者における、cd8陽性t細胞依存性免疫応答を増強させるための方法及び医薬組成物 Pending JP2022517324A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024151582A JP2024170509A (ja) 2019-01-03 2024-09-03 癌を患っている被験者における、cd8陽性t細胞依存性免疫応答を増強させるための方法及び医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305003 2019-01-03
EP19305003.6 2019-01-03
PCT/EP2020/050039 WO2020141199A1 (en) 2019-01-03 2020-01-02 Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024151582A Division JP2024170509A (ja) 2019-01-03 2024-09-03 癌を患っている被験者における、cd8陽性t細胞依存性免疫応答を増強させるための方法及び医薬組成物

Publications (2)

Publication Number Publication Date
JP2022517324A JP2022517324A (ja) 2022-03-08
JP2022517324A5 true JP2022517324A5 (https=) 2022-11-11

Family

ID=65200739

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021539056A Pending JP2022517324A (ja) 2019-01-03 2020-01-02 癌を患っている被験者における、cd8陽性t細胞依存性免疫応答を増強させるための方法及び医薬組成物
JP2024151582A Pending JP2024170509A (ja) 2019-01-03 2024-09-03 癌を患っている被験者における、cd8陽性t細胞依存性免疫応答を増強させるための方法及び医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024151582A Pending JP2024170509A (ja) 2019-01-03 2024-09-03 癌を患っている被験者における、cd8陽性t細胞依存性免疫応答を増強させるための方法及び医薬組成物

Country Status (12)

Country Link
US (2) US20220073626A1 (https=)
EP (2) EP4059569A1 (https=)
JP (2) JP2022517324A (https=)
KR (1) KR20220008253A (https=)
CN (1) CN113574386A (https=)
AU (1) AU2020205150A1 (https=)
BR (1) BR112021013157A8 (https=)
CA (1) CA3125476A1 (https=)
IL (1) IL284556A (https=)
MX (1) MX2021008121A (https=)
SG (1) SG11202107257UA (https=)
WO (1) WO2020141199A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022192353A1 (en) * 2021-03-09 2022-09-15 Mayo Foundation For Medical Education And Research Biomarkers for identifying and treating cancer patients
CN114397462A (zh) * 2022-03-02 2022-04-26 上海科技大学 来那度胺或其类似物在作为免疫调节剂中的应用
US20260071280A1 (en) * 2022-09-07 2026-03-12 Novigenix Sa Methods to predict response to icbt of a patient having cancer
EP4583914A1 (en) * 2022-09-08 2025-07-16 Board of Regents, The University of Texas System Compositions for treating cancer and methods of using the same
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
WO2025029618A1 (en) * 2023-07-28 2025-02-06 Pinetree Therapeutics, Inc. Non-receptor tyrosine kinase compositions for targeted lysosomal degradaton and methods of use thereof

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927A (en) 1849-12-04 Improvement in pumps for raising water
US6649A (en) 1849-08-14 Arrangement of steam-boiler
US138A (en) 1837-03-08 Barnabas s
US69A (en) 1836-10-27 Machine eor picking or breaking wool and ginned or seedless cotton
US366A (en) 1837-08-31 Quadrant hinge foe
US5866A (en) 1848-10-17 Dentist s deill
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4888278A (en) 1985-10-22 1989-12-19 University Of Massachusetts Medical Center In-situ hybridization to detect nucleic acid sequences in morphologically intact cells
US6280929B1 (en) 1986-01-16 2001-08-28 The Regents Of The University Of California Method of detecting genetic translocations identified with chromosomal abnormalities
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5132432A (en) 1989-09-22 1992-07-21 Molecular Probes, Inc. Chemically reactive pyrenyloxy sulfonic acid dyes
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5338854A (en) 1991-02-13 1994-08-16 Molecular Probes, Inc. Fluorescent fatty acids derived from dipyrrometheneboron difluoride dyes
US5427932A (en) 1991-04-09 1995-06-27 Reagents Of The University Of California Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5262357A (en) 1991-11-22 1993-11-16 The Regents Of The University Of California Low temperature thin films formed from nanocrystal precursors
US5505928A (en) 1991-11-22 1996-04-09 The Regents Of University Of California Preparation of III-V semiconductor nanocrystals
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US6048616A (en) 1993-04-21 2000-04-11 Philips Electronics N.A. Corp. Encapsulated quantum sized doped semiconductor particles and method of manufacturing same
US5472842A (en) 1993-10-06 1995-12-05 The Regents Of The University Of California Detection of amplified or deleted chromosomal regions
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5571018A (en) 1994-11-23 1996-11-05 Motorola, Inc. Arrangement for simulating indirect fire in combat training
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5690807A (en) 1995-08-03 1997-11-25 Massachusetts Institute Of Technology Method for producing semiconductor particles
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US5800996A (en) 1996-05-03 1998-09-01 The Perkin Elmer Corporation Energy transfer dyes with enchanced fluorescence
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5830912A (en) 1996-11-15 1998-11-03 Molecular Probes, Inc. Derivatives of 6,8-difluoro-7-hydroxycoumarin
US5696157A (en) 1996-11-15 1997-12-09 Molecular Probes, Inc. Sulfonated derivatives of 7-aminocoumarin
US5866366A (en) 1997-07-01 1999-02-02 Smithkline Beecham Corporation gidB
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
US6322901B1 (en) 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6617583B1 (en) 1998-09-18 2003-09-09 Massachusetts Institute Of Technology Inventory control
US6114038A (en) 1998-11-10 2000-09-05 Biocrystal Ltd. Functionalized nanocrystals and their use in detection systems
US6855202B2 (en) 2001-11-30 2005-02-15 The Regents Of The University Of California Shaped nanocrystal particles and methods for making the same
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
AU4701200A (en) 1999-05-07 2000-11-21 Quantum Dot Corporation A method of detecting an analyte using semiconductor nanocrystals
US7214477B1 (en) 1999-07-26 2007-05-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Layered device with capture regions for cellular analysis
EP1218743B1 (en) 1999-07-26 2006-05-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Layered device with capture regions for cellular analysis
US6969615B2 (en) 1999-07-26 2005-11-29 20/20 Genesystems, Inc. Methods, devices, arrays and kits for detecting and analyzing biomolecules
US7838222B2 (en) 1999-07-26 2010-11-23 United States of America/ NIH Methods, devices and kits for multiplex blotting of biological samples from multi-well plates
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6225198B1 (en) 2000-02-04 2001-05-01 The Regents Of The University Of California Process for forming shaped group II-VI semiconductor nanocrystals, and product formed using process
US6306736B1 (en) 2000-02-04 2001-10-23 The Regents Of The University Of California Process for forming shaped group III-V semiconductor nanocrystals, and product formed using process
JP2004500109A (ja) 2000-03-22 2004-01-08 クァンタム・ドット・コーポレイション ビーズベースの核酸アッセイにおける半導体ナノクリスタルの使用方法
JP2003535063A (ja) 2000-06-01 2003-11-25 ザ・ボード・オブ・リージェンツ・フォー・オクラホマ・ステート・ユニバーシティー 放射線医薬としてのナノ粒子のバイオコンジュゲート
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
EP1311487B1 (en) 2000-08-04 2008-11-26 Molecular Probes, Inc. Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings
US6942970B2 (en) 2000-09-14 2005-09-13 Zymed Laboratories, Inc. Identifying subjects suitable for topoisomerase II inhibitor treatment
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US20020083888A1 (en) 2000-12-28 2002-07-04 Zehnder Donald A. Flow synthesis of quantum dot nanocrystals
US6670113B2 (en) 2001-03-30 2003-12-30 Nanoprobes Enzymatic deposition and alteration of metals
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
US6709929B2 (en) 2001-06-25 2004-03-23 North Carolina State University Methods of forming nano-scale electronic and optoelectronic devices using non-photolithographically defined nano-channel templates
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
JP4567436B2 (ja) 2001-07-20 2010-10-20 ライフ テクノロジーズ コーポレーション 発光ナノ粒子およびそれらの調製方法
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
GB0229734D0 (en) 2002-12-23 2003-01-29 Qinetiq Ltd Grading oestrogen and progesterone receptors expression
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US7257268B2 (en) 2003-02-28 2007-08-14 Aperio Technologies, Inc. Systems and methods for image pattern recognition
DK1601450T3 (da) 2003-03-10 2013-09-08 Expression Pathology Inc Flydende vævspræparat ud fra histopatologisk bearbejdede biologiske prøver, væv og celler
US7642064B2 (en) 2003-06-24 2010-01-05 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest
DK1636586T3 (da) 2003-06-24 2009-11-23 Ventana Med Syst Inc Enzymkatalyseret metaldeponering til foröget in situ-detektion af immunhistokemisker epitoper og nucleinsyresekvenser
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
CA2606018A1 (en) 2005-04-28 2006-11-02 Ventana Medical Systems, Inc. Nanoparticle conjugates
CA2609702C (en) 2005-04-28 2013-05-28 Ventana Medical Systems, Inc. Antibody conjugates via heterobifunctional peg linkers
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
US20070117153A1 (en) 2005-11-23 2007-05-24 Christopher Bieniarz Molecular conjugate
WO2007076128A2 (en) 2005-12-23 2007-07-05 Nanostring Technologies, Inc. Nanoreporters and methods of manufacturing and use thereof
JP5700911B2 (ja) 2005-12-23 2015-04-15 ナノストリング テクノロジーズ,インコーポレーテッド 配向され、固定化された巨大分子を含む組成物とその製造法
US7741045B2 (en) 2006-11-16 2010-06-22 General Electric Company Sequential analysis of biological samples
US7629125B2 (en) 2006-11-16 2009-12-08 General Electric Company Sequential analysis of biological samples
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
CA2687292C (en) 2007-04-10 2017-07-04 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
US8023714B2 (en) 2007-06-06 2011-09-20 Aperio Technologies, Inc. System and method for assessing image interpretability in anatomic pathology
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US8519115B2 (en) 2008-08-14 2013-08-27 Nanostring Technologies, Inc. Stable nanoreporters
JP5551702B2 (ja) 2008-09-16 2014-07-16 ヒストロックス,インコーポレイテッド. バイオマーカー発現の再現性のある定量
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
CA2749601C (en) 2009-01-14 2020-07-21 Stephen M. Hewitt Ratio based biomarkers and methods of use thereof
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille Pd−1抗体およびpd−l1抗体ならびにその使用
JP5748653B2 (ja) 2009-04-10 2015-07-15 協和発酵キリン株式会社 抗tim−3抗体を用いた血液腫瘍治療法
US20110111435A1 (en) 2009-11-06 2011-05-12 SlidePath Limited Detecting Cell Surface Markers
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
AU2011262758B8 (en) 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US9783578B2 (en) 2010-06-25 2017-10-10 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012168944A1 (en) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
CA2868408A1 (en) 2012-03-29 2013-10-03 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the bc loop of human pd1
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
EP3677310A1 (en) * 2012-10-08 2020-07-08 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN113355357B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
EP2840140B2 (en) 2012-12-12 2023-02-22 The Broad Institute, Inc. Crispr-Cas based method for mutation of prokaryotic cells
EA031470B1 (ru) 2013-03-15 2019-01-31 Бристол-Майерс Сквибб Компани Ингибиторы ido
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
HUP1300432A2 (hu) 2013-07-10 2015-01-28 Tamas Kardos Downhill kerékpár szerkezet javított felfüggesztéssel
HUE038169T2 (hu) 2013-09-06 2018-09-28 Aurigene Discovery Tech Ltd 1,2,4-Oxadiazol származékok mint immunomodulátorok
EA029661B1 (ru) 2013-09-06 2018-04-30 Ауриген Дискавери Текнолоджиз Лимитед Производные 1,3,4-оксадиазола и 1,3,4-тиадиазола в качестве иммуномодуляторов
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
WO2015048577A2 (en) 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
KR102357893B1 (ko) 2014-08-05 2022-02-04 맵퀘스트 에스아 Pd-1 에 결합하는 면역학적 시약
WO2017055404A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
WO2017075451A1 (en) * 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
EA201990978A1 (ru) * 2016-11-08 2019-12-30 Актиджен Лтд Антитела против pd-1
JOP20190134A1 (ar) * 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
US20180333503A1 (en) * 2017-05-16 2018-11-22 Immunogen, Inc. Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations
JP2020522495A (ja) * 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗lag−3抗体、pd−1経路阻害剤および免疫療法剤の組み合わせを含む組成物
WO2018223182A1 (en) * 2017-06-05 2018-12-13 The Council Of The Queensland Institute Of Medical Research A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf- kb ligand) antagonist for cancer therapy or prophylaxis and uses therefor.
US20220023342A1 (en) * 2018-11-30 2022-01-27 Institut Gustave Roussy Anti-neuropilin-1 and anti-programmed cell death-1 combination therapy for treating cancer

Similar Documents

Publication Publication Date Title
JP2022517324A5 (https=)
JP7854419B2 (ja) 最適化された抗tl1a抗体
US10870703B2 (en) Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
JP6767362B2 (ja) リンパ球における阻害経路の中和
JP2021008487A (ja) 抗nkg2a抗体を使用した治療計画
JP2019511212A (ja) ヒトポリオウイルス受容体(pvr)に特異的な抗体
JP7754506B2 (ja) ポリオウイルス受容体(pvr)に対する抗体およびその使用
WO2020168555A1 (zh) Cd3抗原结合片段及其应用
KR20130043168A (ko) 이원 가변 도메인 면역글로불린 및 이의 용도
CN116848145A (zh) 免疫球蛋白轻链抗体及其用途
JP2021530428A (ja) 頭頸部癌の処置
CN115698075A (zh) 涉及抗icos和抗pd1抗体,任选地进一步涉及抗tim3抗体的癌症的组合治疗
CN104487092B (zh) 对于由阻碍整合素α8β1功能引起的纤维化的抑制
JP7405434B2 (ja) ストレス関連障害および癌を治療するための材料および方法
US20230192833A1 (en) New anti-VEGFC antibodies and uses thereof
JP7704751B2 (ja) 再発性および/または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用
RU2021119549A (ru) Способы и фармацевтические композиции для усиления cd8+ t-клеточных иммунных ответов у субъектов, страдающих от рака
JP2023530997A5 (https=)
WO2026073315A1 (en) Inhibitory epha2 antigen-binding agents and uses thereof
JP2026513770A (ja) 抗ctla4抗体を使用して黒色腫を治療する方法
KR20250162623A (ko) 항-ctla4 항체를 사용하여 흑색종을 치료하는 방법
WO2025186779A1 (en) Oncolytic viruses expressing immunomodulators and use for treating advanced solid tumor
JP2025069950A (ja) Api5タンパク質に特異的に結合する抗体
WO2026073314A1 (en) Activating epha2 antigen-binding agents and uses thereof
CN118324910A (zh) Ccr8抗体的应用